What is claimed is:

1. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 100 mg to about 600 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is 65:35 to 88:12 by weight of free base.

2. The composition of claim 1, wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 100 mg to about 400 mg by weight of free base.

3. The composition of claim 1 or 2, wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 100 mg by weight of free base.

4. The composition of claim 1 or 2, wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg by weight of free base

5. The composition of claim 1 or 2, wherein the composition is a tablet comprising about 400 mg of a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, by weight of free base.

6. The composition of any one of the preceding claims, wherein the (R)-(+)-amisulpride is crystalline (R)-(+)-amisulpride of crystal Form A; and the (S)-(-)-amisulpride is crystalline (S)-(-)-amisulpride of crystal Form A';

wherein Form A is characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 7.0±0.2°, 9.7±0.2°, and 15.4±0.2°; and

Form A' is characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 7.0±0.2°, 9.7±0.2°, and 15.4±0.2°.

7. The composition of any one of the preceding claims, wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is 85:15 by weight of free base.

8. Use of a composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the alleviation of bipolar disorder in a subject in need thereof;

wherein the medicament is adapted such that the total daily combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, to be administered is about 100 mg to about 600 mg by weight of free base;

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the medicament is 65:35 to 88:12 by weight of free base; and

wherein the medicament is adapted for administration to the subject as a dosage unit form comprising about 100 mg, about 200 mg, about 300 mg, or about 400 mg of a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, by weight of free base.

9. The use of claim 8, wherein the medicament is adapted such that the total daily combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, to be administered is about 100 mg to about 600 mg by weight of free base, and the medicament is adapted for administration once daily or twice daily.

10. The use of claim 8 or 9, wherein the medicament is adapted such that the total daily combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, to be administered is about 200 mg by weight of free base, and the medicament is adapted for administration once daily.

11. The use of claim 8 or 9, wherein the medicament is adapted such that the total daily combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, to be administered is about 400 mg by weight of free base, and the medicament is adapted for administration once daily.

12. Use of a composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the alleviation of bipolar disorder in a subject in need thereof;

wherein the medicament is adapted such that the total daily combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, to be administered is about 200 mg by weight of free base;

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the medicament is 85:15 by weight of free base; and

wherein the medicament is adapted for administration once daily to the subject as a dosage unit form comprising about 100 mg or about 200 mg of a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, by weight of free base.

13. The use of claim 12, wherein the medicament is adapted for administration of about 200 mg as multiple dosage unit forms once daily.

14. Use of a composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the alleviation of bipolar depression in a subject in need thereof;

wherein the medicament is adapted such that the total daily combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, to be administered is about 400 mg by weight of free base;

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the medicament is 85:15 by weight of free base; and

wherein the medicament is adapted for administration once daily to the subject as a dosage unit form comprising about 100 mg or about 200 mg of a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, by weight of free base.

15. The use of claim 12 or 14,

wherein the dosage unit form comprises about 100 mg of a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, by weight of free base.

16. The use of claim 12 or 14,

wherein the dosage unit form comprises about 200 mg of a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, by weight of free base.

17. The use of claim 14, wherein the medicament is adapted for administration of about 400 mg as multiple dosage unit forms once daily.

18. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is 65:35 to 88:12 by weight of free base.

19. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is 65:35 to 85:15 by weight of free base.

20. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is 75:25 to 85:15 by weight of free base.

21. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is 80:20 to 85:15 by weight of free base.

22. The composition of any one of claims 18 to 21 wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg by weight of free base.

23. The composition of any one of claims 18 to 21 wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 400 mg by weight of free base.

24. The composition of any one of claims 18 to 23 wherein the composition comprises:

about 170 mg to about 340 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

about 30 mg to about 60 mg (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base.

25. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 600 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is about 85:15 by weight of free base.

26. A composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg to about 400 mg by weight of free base; and

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the composition is about 85:15 by weight of free base.

27. The composition of claim 26 wherein the composition comprises:

about 170 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

about 30 mg of (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base.

28. The composition of claim 26 wherein the composition comprises:

about 340 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

about 60 mg of (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base.

29. Use of a composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the alleviation of bipolar disorder in a subject in need thereof;

wherein the medicament comprises:

an amount about 85 mg to about 600 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

an amount about 15 mg to about 100 mg (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride in the medicament is about 65:35 to about 88:12 by weight of free base.

30. The use of any one of claims 8 to 11, or 29, wherein the enantiomeric ratio of (R)-(+)-amisulpride to (S)-(-)-amisulpride is about 85:15 by weight of free base.

31. The use of claim 29 wherein the medicament comprises:

an amount about 170 mg to about 340 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

an amount about 30 mg to about 60 mg (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base.

32. The use of claim 29 or 31 wherein the medicament comprises:

an amount about 170 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

an amount about 30 mg of (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base.

33. The use of claim 29 or 31 wherein the medicament comprises:

an amount about 340 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

an amount about 60 mg of (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base.

34. The use of claim 29 wherein the medicament comprising a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg or about 700 mg by weight of free base.

35. The use of claim 29 or 30 wherein the medicament comprising a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 200 mg by weight of free base.

36. The use of claim 29 or 30 wherein the medicament comprising a combined amount of (R)-(+)-amisulpride and (S)-(-)-amisulpride, or pharmaceutically acceptable salts thereof, is about 400 mg by weight of free base.

37. The use of any one of claims 8 to 11, or 30 to 36, wherein the bipolar disorder is bipolar depression.

38. The use of any one of claims 29 to 37 wherein the medicament is adapted to provide in the subject after administration an occupancy of dopamine D2 receptors about 20% to about 60%.

39. The use of any one of claims 29 to 38 wherein the medicament is adapted to provide in the subject after administration a suppression of the time in rapid eye movement (REM) sleep as characterized by a decrease in REM sleep by an amount greater than 10 minutes.

40. The use of any one of claims 29 to 39 wherein the medicament is adapted to provide in the subject after administration a suppression of the time in rapid eye movement (REM) sleep as characterized by a decrease in total REM sleep time relative to total sleep time by an amount greater than 5 %.

41. The use of any one of claims 29 to 40 wherein the medicament is adapted for administration once daily.

42. Use of a composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the alleviation of bipolar disorder in a subject in need thereof;

wherein the medicament comprises:

an amount about 170 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

an amount about 30 mg of (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the medicament is adapted for administration once daily.

43. Use of a composition comprising:

(R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof; and

(S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for the alleviation of bipolar disorder in a subject in need thereof;

wherein the medicament comprises:

an amount about 340 mg of (R)-(+)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base; and

an amount about 60 mg of (S)-(-)-amisulpride, or a pharmaceutically acceptable salt thereof, by weight of free base;

wherein the medicament is adapted for administration once daily.

44. The use of any one of claims 8 to 11, 29 to 43, or the composition of any one of claims 25 to 28

wherein the (R)-(+)-amisulpride is crystalline (R)-(+)-amisulpride of crystal Form A; and the (S)-(-)-amisulpride is crystalline (S)-(-)-amisulpride of crystal Form A';

wherein Form A is characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 7.0±0.2°, 9.7±0.2°, and 15.4±0.2°; and

Form A' is characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 7.0±0.2°, 9.7±0.2°, and 15.4±0.2°.